Abstract
Purpose To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D95 of the PTV. Results Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.
Original language | English |
---|---|
Pages (from-to) | 276-280 |
Number of pages | 5 |
Journal | Radiotherapy and Oncology |
Volume | 116 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- Continual reassessment method
- Non-small cell lung cancer (NSCLC)
- Phase I study
- SBRT
- Stereotactic body radiotherapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Radiology Nuclear Medicine and imaging